VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has signed a nonbinding letter of intent with Denmark-based Missionpharma A/S to explore the development and global commercialization of its prototype lateral flow technology for detecting NETosis, a process associated with inflammation. The collaboration will initially focus on evaluating the finger-prick diagnostic test for neonatal sepsis, with potential applications in low- and middle-income countries and humanitarian emergency settings.
The agreement could significantly impact global health by accelerating access to affordable diagnostic tools in resource-constrained regions, where early identification and management of neonatal sepsis remain critical challenges. Missionpharma, which supplies healthcare products to United Nations agencies, government health ministries and other institutions, could support low-cost manufacturing, clinical studies and distribution. This partnership leverages Missionpharma's established supply chains and Volition's innovative epigenetics platform to address a major unmet need in neonatal care.
Volition's lateral flow prototype recently demonstrated high correlation with its established automated Nu.Q NETs test in critically ill sepsis patients, according to the company. The technology measures circulating nucleosomes and neutrophil extracellular traps as potential early indicators of hyperinflammation, with applications extending beyond centralized laboratory testing. This validation is crucial for translating the technology into a point-of-care format suitable for settings with limited laboratory infrastructure.
For investors, the LOI represents a potential pathway to commercialize Volition's NETosis technology in high-need markets. The company's shares trade on the NYSE American under the ticker VNRX, and detailed quote information is available through VolitionRx Limited (NYSE American: VNRX). The collaboration may open new revenue opportunities and demonstrate the versatility of Volition's epigenetic diagnostics beyond oncology.
Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. More information about Volition can be found at Volition.
The announcement was distributed by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. For full terms and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer. The full press release can be viewed at https://nnw.fm/9AltW.
